<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181558</url>
  </required_header>
  <id_info>
    <org_study_id>01-200</org_study_id>
    <nct_id>NCT00181558</nct_id>
  </id_info>
  <brief_title>Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone</brief_title>
  <official_title>Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to look at the effects (good or bad) that Atrasentan given&#xD;
      alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction&#xD;
      in men with prostate cancer that has spread to the bones.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will be randomized to either receive Atrasentan alone or Atrasentan plus&#xD;
           Zometa.&#xD;
&#xD;
        -  Patients receiving Atrasentan alone will receive this drug in pill form once daily for&#xD;
           12 weeks. Patients will have a physical exam, blood work, and a urine sample performed&#xD;
           once every other week during the first four weeks of medication administration. After&#xD;
           those two initial visits, they will return to the clinic once every 4 weeks to have the&#xD;
           same tests repeated. A bone scan and abdominal-pelvic CT Scan will be done every 12&#xD;
           weeks.&#xD;
&#xD;
        -  After the patient has been taking Atrasentan for 12 weeks, if the disease has not&#xD;
           progressed, they will begin combination treatment of Atrasentan and Zometa.&#xD;
&#xD;
        -  Patients receiving Atrasentan plus Zometa, receive Zometa intravenously and then&#xD;
           immediately start Atrasentan orally once daily as long as they remain on the study.&#xD;
           Patients will return to the clinic twice over the first 4 weeks (once every other week)&#xD;
           to have a physical exam, blood work and urine test performed. After these two initial&#xD;
           visits, they will return to the clinic once every 4 weeks to have the tests repeated and&#xD;
           to receive another treatment of zometa. A bone scan and an abdominal-pelvic CT Scan will&#xD;
           be done once every 12 weeks.&#xD;
&#xD;
        -  Patients participation in this study will last as long as the disease does not progress&#xD;
           and they are not experiencing any serious side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the effects of Atrasentan monotherapy with combination therapy using Atrasentan and Zometa on bone specific alkaline phosphatase.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of Atrasentan monotherapy and combination therapy with Atrasentan and Zometa on PSA doubling time.</measure>
  </secondary_outcome>
  <enrollment>44</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Adenocarcinoma of the Prostate</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrasentan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid (Zometa)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  History of bilateral orchiectomy or current treatment with a GnRH agonist or&#xD;
             antagonist&#xD;
&#xD;
          -  Radiographically documented bone metastases&#xD;
&#xD;
          -  Disease progression according to criteria from the PSA Working Group&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with Atrasentan or Zometa within one year&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0mg/dL&#xD;
&#xD;
          -  Documented cardiovascular disability status of New York Heart Association Class 2&#xD;
&#xD;
          -  Treatment with chemotherapy, radiation, steroids, estrogens, or PC-SPES within 6 weeks&#xD;
&#xD;
          -  Treatment with bisphosphonates or radiopharmaceuticals within 12 weeks&#xD;
&#xD;
          -  History of Paget's disease, hyperthyroidism, hyperparathyroidism, Cushing's syndrome,&#xD;
             hyperprolactinemia or other disorder associated with metabolic bone disease.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Smith, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>May 7, 2010</last_update_submitted>
  <last_update_submitted_qc>May 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Matthew R. Smith, MD, PhD</name_title>
    <organization>Massachusetts General Hospital, Boston, MA 02114</organization>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>bone metastases</keyword>
  <keyword>Atrasentan</keyword>
  <keyword>Zometa</keyword>
  <keyword>Androgen Independent Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Atrasentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

